EXACT Sciences Co. Expected to Earn FY2019 Earnings of $0.29 Per Share (EXAS)

EXACT Sciences Co. (NASDAQ:EXAS) – Stock analysts at Leerink Swann lifted their FY2019 earnings per share (EPS) estimates for shares of EXACT Sciences in a research note issued on Tuesday. Leerink Swann analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.29 for the year, up from their prior forecast of $0.26. Leerink Swann currently has a “Outperform” rating and a $67.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Bank of America boosted their target price on EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, November 29th. Robert W. Baird cut EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research note on Monday, November 13th. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, January 2nd. Benchmark set a $65.00 price target on EXACT Sciences and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Finally, BidaskClub cut EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $52.84.

EXACT Sciences (NASDAQ:EXAS) traded down $3.61 on Thursday, hitting $44.56. The stock had a trading volume of 2,076,383 shares, compared to its average volume of 3,492,874. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences has a 52-week low of $18.30 and a 52-week high of $63.60. The stock has a market capitalization of $5,530.00, a PE ratio of -39.65 and a beta of 0.58.

In other news, insider Kevin T. Conroy sold 125,402 shares of the company’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $52.79, for a total transaction of $6,619,971.58. Following the transaction, the insider now directly owns 955,454 shares of the company’s stock, valued at $50,438,416.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kevin T. Conroy sold 110,439 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $50.49, for a total value of $5,576,065.11. Following the transaction, the insider now directly owns 940,491 shares in the company, valued at $47,485,390.59. The disclosure for this sale can be found here. Over the last three months, insiders sold 662,694 shares of company stock worth $35,934,015. Insiders own 4.00% of the company’s stock.

Several large investors have recently made changes to their positions in the company. First Trust Advisors LP lifted its holdings in shares of EXACT Sciences by 14.0% during the fourth quarter. First Trust Advisors LP now owns 78,328 shares of the medical research company’s stock valued at $4,115,000 after purchasing an additional 9,630 shares in the last quarter. Swiss National Bank lifted its holdings in shares of EXACT Sciences by 3.1% during the fourth quarter. Swiss National Bank now owns 202,819 shares of the medical research company’s stock valued at $10,656,000 after purchasing an additional 6,100 shares in the last quarter. Biondo Investment Advisors LLC lifted its holdings in shares of EXACT Sciences by 158.8% during the fourth quarter. Biondo Investment Advisors LLC now owns 94,735 shares of the medical research company’s stock valued at $4,977,000 after purchasing an additional 58,135 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of EXACT Sciences by 40.0% during the fourth quarter. California Public Employees Retirement System now owns 266,481 shares of the medical research company’s stock valued at $14,001,000 after purchasing an additional 76,143 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of EXACT Sciences by 315.7% during the fourth quarter. Teacher Retirement System of Texas now owns 40,470 shares of the medical research company’s stock valued at $2,126,000 after purchasing an additional 30,735 shares in the last quarter. 82.32% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/08/exact-sciences-co-expected-to-earn-fy2019-earnings-of-0-29-per-share-exas.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply